The study found that 20.5% of patients achieved a pathological complete response (pCR) and that a PAM50 HER2-enriched genomic profile, determined in baseline pre-treatment tumour samples, was found associated with a higher likelihood of achieving a pCR than the other subtypes (46% vs. 14%). Here, ERBB2 is linked to neoplasm.